Authors
Latest:
Dr. Erickson on the Varying Safety Profiles of Select PARP Inhibitors in Ovarian CancerBritt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer.
Latest:
Dr Randall on PROs With Pembrolizumab Plus Chemoradiotherapy in Cervical CancerLeslie M. Randall, MD, MAS, discusses patient-reported outcomes from the ENGOT-cx11/GOG 3047/KEYNOTE-A18 trial in locally advanced cervical cancer.
Latest:
Dr Bahadur on the Shift in Frontline CDK4/6 Inhibitor Selection in HR+/ HER2– Breast Cancer Breast CancerShakeela Bahadur, MD, discusses how recent data have informed the selection of approved CDK4/6 inhibitors in the frontline setting for patients with metastatic hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced MelanomaSajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.
Latest:
The Future of Liver Function Assessments in HCCExperts emphasize the importance of using multiple liver function assessments for more comprehensive patient evaluation in hepatocellular carcinoma treatment.
Latest:
5 Tips for a First-Year FellowChristopher Su, MD, MPH, highlights 5 tips for first-year oncology fellows.
Latest:
The Importance of Lung Cancer Screening in Individuals Exposed to the World Trade Center DisasterInvestigators evaluated risk factor–based guidelines and risk model–based strategies for lung cancer screening in World Trade Center–exposed responders.
Latest:
Dr. Davies on the Potential Utility of ERK Inhibitors in MelanomaMichael A. Davies, MD, PhD, discusses the potential utility of ERK inhibitors in melanoma.
Latest:
Dr. Packiam on Safety of Cabazitaxel/Gemcitabine Plus Pembrolizumab in Urothelial CarcinomaVignesh Packiam, MD, discusses the adverse effects associated with cabazitaxel and gemcitabine with pembrolizumab in patients who are unresponsive to docetaxel with non-muscle invasive urothelial carcinoma.
Latest:
Contralateral Breast Cancer Treatment With Germline Mutation CarriersSiddartha Yadav, MD, FACP, of Mayo Clinic, discusses personalizing treatment for patients with germline–mutant contralateral breast cancer.
Latest:
Dr Leick on Limitations Associated With CAR T-Cell Therapy in Hematologic MalignanciesMark Leick, MD, discusses the challenges and limitations associated with the use of CAR T-cell therapy across hematologic malignancies, highlighting how ongoing research may potentially ameliorate present unmet needs.
Latest:
Dr Eisfeld on Timing of Molecular Testing and the Start of Treatment in AMLAnn-Kathrin Eisfeld, MD, discusses factors to consider when deciding whether to start treatment right away or wait for molecular testing results in patients with acute myeloid leukemia.
Latest:
Basal Cell Carcinoma Clinical PearlsDrs Babakoohi and Atlas share clinical pearls for community oncologists on treating basal cell carcinoma.
Latest:
Dr. Lin on the Limitations of Current Biomarkers in Prostate CancerDaniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.
Latest:
Dr. Mitra on Nadofaragene Firadenovec Plus Anti–PD-1 Therapy in BCG-Unresponsive NMIBCAnirban P. Mitra, MD, PhD, discusses data from an assessment of PD-1 and PD-L1 status on transurethral resection specimens collected from patients with non–muscle-invasive bladder cancer who received nadofaragene firadenovec as part of a phase 3 trial.
Latest:
Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCCCristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
Latest:
Molecular Approaches May Increase Responsiveness to Immunotherapy for Patients With Metastatic MelanomaThe recent development of therapeutics which stimulate immune response to tumor cells has revolutionized the treatment landscape for cutaneous melanoma.
Latest:
EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S MutationExpert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.
Latest:
DNA Alterations and Selection of PARP Inhibitors in mCRPCExpert perspectives on how DNA alterations may inform the selection and use of PARP inhibitors in metastatic CRPC.
Latest:
Dr Miller on the Efficacy of Selinexor in TP53 Wild-Type Endometrial CancerDavid S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.
Latest:
Dr Nasioudis on the Use of SLNB in Metastatic Vulvar Squamous Cell CarcinomaDimitrios Nasioudis, MD, discusses outcomes of patients with metastatic vulvar squamous cell carcinoma who underwent sentinel lymph node biopsy.
Latest:
Dr Marouf on the Efficacy of PD-L1 Inhibition in R/R Extranodal NK/T-cell LymphomaAmira Marouf, MD, PhD student, discusses the efficacy of PD-L1 inhibitors in relapsed/refractory extranodal natural killer/T-cell lymphoma.
Latest:
VIGH, VICC Establish Cancer Research Program in ZambiaVanderbilt University Medical Center and the University of Zambia are partnering on a program to develop a cadre of researchers and educators to lead cancer epidemiology research and training in Zambia and to encourage U.S.-based researchers to engage in cancer research in low- and middle-income countries.
Latest:
Dr Saad on the Potential Predictive Value of IL7 SNPs in RCCEddy Saad, MD, MSc, the potential predictive value of IL-7 SNPs to inform treatment decisions for select patients with renal cell carcinoma.
Latest:
CAR T-Cell Therapy Proves Effective in First Trial in Patients with Resistant Multiple MyelomaStudy establishes rationale for combination approaches targeting multiple proteins — therapy produces responses in 70% of study participants, including those who who relapsed after prior CAR T therapy.
Latest:
Dr Linscott on the Use of Urinary Cell-free Tumor DNA to Predict MRD in High-Risk NMIBCJoshua Linscott, MD, PhD, discusses the use of utDNA to predict MRD prior to repeat TURBT in patients with high-risk non-muscle invasive bladder cancer.
Latest:
Dr. Dzienis on Use of Pembrolizumab with Carboplatin and Paclitaxel in HNSCCMarcin Dzienis, MD, discusses the use of pembrolizumab with carboplatin and paclitaxel in head and neck squamous cell carcinoma .
Latest:
BRONx-CAN Program Aims to Deliver the Best Cancer Treatments EarlyMontefiore Einstein Cancer Center hopes to begin combating systemic inequities and improve cancer outcomes for historically disadvantaged populations by taking a data-driven approach to delivering neoadjuvant therapy in communities that are economically and socially marginalized.
Latest:
The Role of Genetic Profiling in Secondary AMLJames K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
